Introduction
============

The uncinate process is a hook like extension from the lower part of the head of the pancreas, and it extends superiorly and posteriorly behind the superior mesenteric vein (SMV), and ends either to the right side or extending behind the superior mesenteric artery (SMA) [@B1]. Compared with the other parts of the head, the uncinate process is closer to the mesentery. The special anatomical position of uncinate process accounts for the peculiar clinicopathological features of the uncinate process cancer [@B1]-[@B9]. However, few reports have compared the clinicopathological features and prognosis of uncinate process pancreas cancer with those of non-uncinate process pancreatic cancer. Therefore, in this study we investigated the clinicopathological features and prognosis in patients with uncinate process cancer compared to patients with non-uncinate process pancreatic head cancer.

Materials and methods
=====================

Subjects
--------

From January 2010 to December 2014, 160 patients with pancreatic head cancer referred to Peking University First Hospital were included in this study. Among them, 85 patients were pathologically confirmed as pancreatic ductal adenocarcinoma and the other 75 patients were diagnosed by CT imaging and CA 19-9. All patients diagnosed other than ductal adenocarcinoma such as ductal-endocrine carcinoma, intraductal papillary mucinous carcinoma, and signet ring cell carcinomas were excluded. The clinicopathological data were collected from electronic medical record system, and patients who underwent surgical resection were followed up every 3 months.

Based on dedicated pancreatic multi-detector computed tomography (MDCT), patients were classified into two groups: the uncinate process cancer and the non-uncinate process pancreatic head cancer. All CT scans were reviewed blindly by two experienced radiologists, and interpretations were achieved by consensus. Of these 160 patients, 55 patients had tumors located in the uncinate process of the pancreas, including 31 men and 24 women who aged from 23 to 83 years (mean age 63.8 years), and the other 105 patients had non-uncinate process pancreatic head cancers, including 65 men and 40 women who aged from 39 to 85 years (mean age 63.1 years).

Treatment
---------

Of the 55 patients with uncinate process cancer, 24 patients received classical pancreatoduodenectomy, one patient received total pancreatectomy, 11 patients received open bypass, and 19 patients had no operation. In addition, 6 patients underwent combined partial or segmental resection of SMV/PV and reconstruction. Of the 105 patients with non-uncinate process pancreatic head cancer, 36 patients received classical pancreatoduodenectomy, 2 patients received total pancreatectomy, 2 patients received pylorus preserving pancreatoduodenectomy, 19 patients received open bypass and biopsy, 1 patient received only open biopsy without bypass, and 45 patients had no operation. In addition, 7 patients underwent combined partial or segmental resection of SMV/PV and reconstruction (Table [1](#T1){ref-type="table"}).

Adjuvant chemotherapy including six cycles of gemcitabine (1000 mg/m^2^, 30 min intravenous infusion on day 1, 8, and 15) was performed in 17 patients of the 65 patients who underwent resection. 5 patients received only 1-2 cycle chemotherapy and the other 43 patients refused adjuvant chemotherapy. Among the other 95 patients who did not undergo curative resection, only 10 patients received chemotherapy, and the other 85 patients did not receive chemotherapy due to a poor performance or refusing chemotherapy.

Statistical analysis
--------------------

SPSS version 19.0 (IBM Corp.) was used for statistical analysis and data management. The values were presented as the mean ± SD, medians (interquartile range), or numbers and percentages. Chi-Square analysis or Fisher\'s exact test were used to compare categorical data. Continuous variables were compared using the t test or Mann-Whitney test. Survival curves were constructed using the Kaplan-Meier method and the statistical significance of differences in survival was determined using the log-rank test. The Cox-Hazard model was used for the multivariate analysis. A multivariate analysis was conducted using the factors that were significant in the univariate analysis. A two-sided P value less than 0.05 indicated significant difference.

Results
=======

Clinical characteristics of the patients
----------------------------------------

The main clinical characteristics of the patients were shown in Table [2](#T2){ref-type="table"}. Upper abdominal pain, weight loss and jaundice were the three main symptoms, and were not significantly different between the patients with uncinate process cancer and the patients with non-uncinate process pancreatic head cancer. In addition, there were no significant differences in serum bilirubin level, liver function or CA 19-9 between the two groups.

Clinical and pathological features of the tumors
------------------------------------------------

The mean size of tumors in the uncinate process was 3.43 cm (range 1.0-7.3 cm) (Table [3](#T3){ref-type="table"}). In the non-uncinate process pancreatic head, the mean size of tumors was 3.44 cm (range 1.0-7.6 cm). The tumor size was not significantly different between the two groups, as well as the dilation of pancreatic duct and dilation of common bile duct. However, the percentage of vascular (SMV/PV and/or SMA) invasion was significantly higher (P=0.019) in patients with the uncinate process cancer (32/55 patients, 58.2%) than in patients with non-uncinate process pancreatic head cancer (40/105 patients, 38.1%). Moreover, SMA encasement was diagnosed more often (P=0.011) in patients with uncinate process cancer (17/55 patients, 30.9%) than in patients with non-uncinate process pancreatic head cancer (14/105 patients, 13.3%). In addition, the chance of SMV invasion (P=0.026) and PV (P=0.001) invasion were significantly higher in the patients with the uncinate process cancer.

According to the AJCC TNM Staging of Pancreatic Cancer (seventh edition, 2010), 23 uncinate process cancer patients and 44 non-uncinate process pancreatic head cancer patients were diagnosed with stage III or IV disease, respectively. The rate of R0 resection was not significantly different between two groups. However, the rate of R1 resection (with microscopically residual tumor) was significantly higher (P=0.019) in patients with uncinate process cancer (9/55 patients, 16.4%) than in patients with non-uncinate process cancer (5/105 patients, 4.8%). Typical staining of the uncinate process cancer was shown in Fig. [1](#F1){ref-type="fig"}.

Survival of the patients
------------------------

The median follow-up was 15.0 months (range 5-46 months) for the 65 patients who underwent curative resection. At the last follow-up, 48 patients (73.8%) died of pancreatic head cancer recurrence, 3 patients (4.6%) died of other causes, 2 patients (3.1%) were alive with disease and 12 patients (18.5%) were alive with no clinical or radiographic evidence of disease. The median overall survival after resection (R0 and R1) was 16.0 months (95% CI: 13.5-18.5 months).

The median overall survival of patients after R0 resection was 18.0 months (95% CI: 16.2-19.8 months), significant higher than that of patients after R1 resection (11.0 months, 95% CI: 7.4-14.6 months; P=0.001). The overall 1- and 3-year survival rate of the patients after R0 resection was 68.3% and 19.2%, respectively. Although we found no significant differences in clinicopathological characteristics between the two groups after R0 resection (Table [4](#T4){ref-type="table"}), the median overall survival after R0 resection was lower for uncinate process cancer than non-uncinate process pancreatic head cancer (15 months vs. 19 months, P=0.036, Fig. [2](#F2){ref-type="fig"}).

Recurrence of the tumors
------------------------

The median disease-free survival was higher in patients after R0 resection than in patients after R1 resection (median, 13 months vs. 6 months; P\<0.001). The disease-free 1 and 3-year survival rate of the patients after R0 resection was 50.8% and 13.4%, respectively. Follow -up data showed that recurrence occurred in 37 patients (72.5%) of the 51 patients after R0 resection (Table [5](#T5){ref-type="table"}). Notably, locoregional recurrence was the most common for the uncinate process pancreatic head caner, and systemic recurrence was the most common for the non-uncinate process cancer.

Patients with uncinate process cancer had significantly worse disease-free survival (median 11 months) than those with non-uncinate process pancreatic head cancer (median 15 months, P=0.043, Fig. [3](#F3){ref-type="fig"}). Locoregional recurrence had higher frequency (P=0.017) and earlier development (median, 12 months vs. 36 months; P=0.002, Fig. [4](#F4){ref-type="fig"}) in patients with uncinate process cancer than in those with non-uncinate process pancreatic head caner. In addition, systemic recurrence had earlier development (median, 13 months vs. 36 months; P=0.027, Fig. [5](#F5){ref-type="fig"}) in patients with uncinate process cancer, as well as locoregional and sychronous systemic recurrence (P=0.007; Fig. [6](#F6){ref-type="fig"}).

Prognostic factors
------------------

Univariate survival analysis shows that the location, margin status, LN metastasis, and the number of positive lymph node were significant predictors for both disease-free survival and overall survival (Table [6](#T6){ref-type="table"}). Tumor differentiation and vascular cancer embolus correlated with disease-free survival, but not with overall survival. CA 19-9 correlated with overall survival, but not with disease-free survival. Multivariate analysis showed that the location, margin status and LN metastasis were independent prognostic factors for disease-free survival, and the location and LN metastasis were independent prognostic factors for overall survival (Table [7](#T7){ref-type="table"}).

Discussion
==========

The pancreatic primordium consists of two buds: dorsal and ventral. The uncinate process is derived from the ventral bud. Anatomically, the uncinate process represents a hook like extension of the lower part of the pancreatic head and is located closely to the superior mesenteric artery and vein [@B1]. This particular anatomical feature may result in specific clinicopathological features of the uncinate process. Previous studies showed that vascular invasion was frequent in patients with the uncinate process cancer, and the rate of R1 resection was significantly higher in these patients [@B7]-[@B9]. In this study, we confirmed that the percentage of vascular invasion, especially SMA encasement was significantly higher in patients with uncinate process cancer. Furthermore, more patients with uncinate process cancer underwent R1 resection. However, no significant differences were found between the two groups in the incidence of jaundice and the dilatation of common bile duct, inconsistent with previous studies [@B7]-[@B9].

It was suggested that patients with uncinate process cancer had worse prognosis accompanied by earlier and more recurrence than patients with non-uncinate process pancreatic head cancer [@B7], [@B8]. In this study, we found no significant difference in clinicopathological characteristics between the two groups after R0 resection, but the overall survival was lower for the patients with uncinate process cancer, and more and earlier locoregional recurrence was observed in the patients with uncinate process cancer. So far, little is known about the mechanism and cause of recurrence of uncinate process cancer.

Currently, the impact of margin status on overall and disease-free survival remains controversial [@B10]. In this study, we found that patients who underwent R0 resection had better overall survival and disease-free survival than those who underwent R1 resection, in agreement with previous studies [@B11], [@B12]. Furthermore, resection margin was an independent significant prognostic factor in pancreatic cancer [@B13], [@B14]. The goal of operation treatment is to achieve R0 resection. For patients with venous involvement, en bloc resection of PV/SMV was not associated with increased morbidity or mortality compared with patients who did not require vein resection, and the rate of R0 resection and overall survival were not different between the two groups [@B15]-[@B18].

SMA (retroperitoneal/uncinate) margin clearance has become a major concern in the operation treatment for uncinate process cancer. The lymph node metastases and extrapancreatic nerve plexus invasion alongside the SMA have been recognized in numerous studies [@B19]-[@B23]. Furthermore, a meta-analysis of radical resection rates and margin assessment in pancreatic cancer indicated that the most commonly involved margins are the SMA, PV/SMV, and posterior margins [@B24]. However, the division of the retroperitoneal tissues between the uncinate process and SMA with a stapler may leave some areolar and lymphatic tissue and increase the risk of R1 resection [@B25]. Jing *et al.*demonstrated that extended pancreaticoduodenectomy combined with full-length SMA isolation could achieve the goal of R0 resection, and improve the quality of life and survival rate of patients [@B26].

However, the reported R1 rate showed high variation (17-85%) due to the lack of consensus on the definition of microscopic margin involvement and standardized protocols for pathological examination [@B10], [@B27]. R1 rate was highly underreported in some studies, which may lead to the discrepancy between margin status and clinical outcome [@B28]-[@B31]. A series of studies have supported that patients with wider margins (\> 1 mm) have better overall survival and disease-free survival than patients with direct invasion of tumor cells within 1 mm of the resection margin, and many centers have adopted a minimum clearance of more than 1 mm to define R0 resection [@B32]-[@B34]. However, a recent study reported that a margin clearance of 2 mm or more was significantly linked to improved overall survival and the R1 definition might have to be adapted [@B35]. In this study, resection margins including SMA, SMV/PV, pancreatic neck, bile duct, enteric and anterior surface margins were evaluated independently, and R0 resection was defined as a minimum clearance of more than 1 mm.

The limitation of this study is that many patients did not receive adjuvant therapies. Recurrence rate of pancreatic cancer was still high. Adjuvant therapies that impact on recurrence were necessary. It has been proved that adjuvant therapies can improve outcomes, although there is no consensus of standard adjuvant treatment after resection.

In conclusion, compared with non-uncinate process pancreatic head cancer, uncinate process cancer had a significantly higher incidence of vascular invasion. Specifically, the chance of SMA encasement, SMV invasion and PV invasion was significantly higher in patients with uncinate process cancer. In addition, the rate of R1 resection (with microscopically residual tumor) was significantly higher in patients with uncinate process cancer. Furthermore, after R0 resection, patients with uncinate process cancer had a worse prognosis than patients with non-uncinate process pancreatic cancer, which was related to the earlier and more frequent locoregional recurrence.
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![Typical staining of the uncinate process cancer. Magnifications: 1:200 (A, B, C) and 1:40 (D). A: SMV invasion; B: Vascular cancer embolus; C: Perineural invasion; D: Lymph node metastasis.](jcav07p1242g001){#F1}

![Kaplan-Meier curve for overall survival in patients after R0 resection according to the tumor location.](jcav07p1242g002){#F2}
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![Systemic recurrence in patients after R0 resection according to the tumor location.](jcav07p1242g005){#F5}

![Locoregional and sychronous systemic recurrence in patients after R0 resection according to the tumor location.](jcav07p1242g006){#F6}

###### 

The types of treatments for the patients.

                            Uncinate (n=55)   Non-uncinate (n=105)   *P*-value
  ------------------------- ----------------- ---------------------- -----------
  Operation                 36 (65.5%)        60 (57.1%)             0.396
  Open bypass               11 (20.0%)        19 (18.1%)             0.832
  Open biopsy only          0                 1 (1.0%)               
  Resection                 25 (45.5%)        40 (38.1%)             0.400
  R0 resection              16 (29.1%)        35 (33.3%)             0.599
  R1 resection              9 (16.4%)         5 (4.8%)               0.019
  Non-resection             30(54.5%)         65(61.9%)              0.400
  PPPD                      0                 2 (1.9%)               
  Whipple\'s operation      24 (43.6%)        36 (34.3%)             
  Total pancreatectomy      1 (1.8%)^a^       2 (1.9%)^b^            
  SMV and/or PV resection   6 (10.9%)         7 (6.6%)               0.372

PPPD, pylorus-preserving Pancreatoduodenectomy; ^a^synchronous ductal adenocarcinoma located at body; ^b^synchronous IPMN located at body and tail.

###### 

Clinical characteristics of the patients.

                              Uncinate (n=55)       Non-uncinate (n=105)   *P*-value
  --------------------------- --------------------- ---------------------- -----------
  Age (mean, years)           63.8±11.1             63.1±10.5              0.701
  Gender (M:F)                1.29:1                1.63:1                 0.503
  Symptoms                                                                 
  abdominal pain              27 (49.1%)            55 (52.4%)             0.741
  jaundice                    38 (69.1%)            66 (62.9%)             0.488
  weight loss                 36 (65.5%)            58 (54.7%)             0.239
  anorexia                    11 (20.0%)            17 (16.2%)             0.662
  nausea                      10 (18.2%)            16 (15.2%)             0.656
  Symptom duration (months)   1.0 (0.7-3.0)         1.0 (0.7-4.0)          0.504
  Laboratory examination                                                   
  ALT (IU/L)                  102.0 (53.0-198.0)    91.0 (33.0-202.0)      0.417
  AST (IU/L)                  84.0 (34.0-133.0)     72.0 (28.0-130.5)      0.461
  TBIL (umol/L)               121.8 (22.7-198.3)    115.0 (18.1-216.1)     0.986
  DBIL (umol/L)               89.9 (6.8-131.0)      69.0(8.7-161.4)        0.857
  CA 19-9 (U/ml)              375.3 (131.2-828.8)   295.5 (119.5-1000)     0.889

ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; CA 19-9, carbohydrate antigen.

###### 

The features of the tumors.

                              Uncinate (n=55)   Non-uncinate(n=105)   *P*-value
  --------------------------- ----------------- --------------------- -----------
  Tumor size (cm)             3.43±1.32         3.44±1.31             0.890
  Vascular invasion           32 (58.2%)        40 (38.1%)            0.019
  SMV invasion                30 (54.5%)        38 (36.2%)            0.026
  PV invasion                 25 (45.5%)        21 (20.0%)            0.001
  SMA encasement^c^           17 (30.9%)        14 (13.3%)            0.011
  Duodenal invasion           22 (40.0%)        36 (34.3%)            0.493
  Distant metastasis          12 (21.8%)        29 (27.6%)            0.453
  Pancreatic duct dilation    30 (54.5%)        62 (59.0%)            0.616
  Common bile duct dilation   45 (81.8%)        78 (74.3%)            0.328
  biliary drainage            14 (25.5%)        29 (27.6%)            0.852
  AJCC stage(7th edition)                                             0.556
  I/II                        32 (58.2%)        61 (58.1%)            
  III                         11 (20.0%)        15 (14.3%)            
  IV                          12 (21.8%)        29 (27.6%)            

^c^tumor contact with SMA \>180°. AJCC, American Joint Committee on Cancer.

###### 

Clinicopathological characteristics of patients after R0 resection.

  -------------------------------------------------------------------------------------
                                   Uncinate (n=16)    Non-uncinate (n=35)   *P*-value
  -------------------------------- ------------------ --------------------- -----------
  Age (mean, years)                67.2±7.4           65.5±8.9              0.506

  Gender (M:F)                     1.3:1              2.9:1                 0.329

  Operative time (min)             397.3±98.1         396.6±139.0           0.986

  Peri-operative bleeding (ml)     400 (300-875)      400 (200-600)         0.758

  SMV and/or PV resection          5 (31.3%)          6 (17.1%)             0.288

  Complication                     5 (31.3%)          16 (45.7%)            0.375

  Pathological tumor size (cm)     3.70±1.73          3.35±1.80             0.515

  Pathological tumor stage                                                  0.694

  T1/T2                            13 (81.3%)         30(85.7%)             

  T3                               3 (18.8%)          5 (14.3%)             

  LN metastasis (+)                4 (25.0%)          16 (45.7%)            0.221

  Number of lymph nodes examined   14.7±9.1           12.5±6.0              0.597

  Number of positive lymph nodes   0.5±1.0            1.0±1.3               0.195

  Histology                                                                 0.742

  well/well-moderate               5 (31.3%)          9 (25.7%)             

  moderate/moderate-poor           11(68.8%)          26 (74.3%)            

  Perineural invasion(+)           13 (81.3%)         27 (77.1%)            \>0.99

  Vascular cancer embolus          4 (25.0%)          8 (22.9%)             \>0.99

  AJCC stage                                                                0.322

  IB                               3 (18.8%)          3 (8.6%)              

  IIA                              9 (56.3%)          16 (45.7%)            

  IIB                              4 (25.0%)          16 (45.7%)            

  Chemotherapy                     6 (37.5%)          11 (31.4%)            0.671

  Follow-up time\                  13 (range, 5-31)   15 (range, 3-46)      
  (median, months)                                                          
  -------------------------------------------------------------------------------------

AJCC, American Joint Committee on Cancer.

###### 

Recurrence after R0 resection.

                                                    Uncinate (n=16)   Non-uncinate (n=35)   *P*-value
  ------------------------------------------------- ----------------- --------------------- -----------
  Overall recurrence                                14 (87.5%)        23 (65.7%)            0.176
  Locoregional recurrence                           12 (75.0%)        13 (37.1%)            0.017
  Systemic recurrence                               10 (62.5%)        14 (40%)              0.226
  Liver                                             9 (56.3%)         13 (37.1%)            0.235
  lung                                              0                 2 (5.7%)              \>0.99
  bone                                              2 (12.5%)         2 (5.7%)              0.581
  Locoregional and sychronous systemic recurrence   8 (50.0%)         8 (22.9%)             0.102

###### 

Univariate analyses of disease-free and overall survival of patients after resection.

                            disease-free survival   overall survival                                                                         
  ------------------------- ----------------------- ---------------------- --------------------- --------------------- --------------------- -------
  Age                                                                      1.004 (0.972-1.036)   0.829                 1.012 (0.980-1.045)   0.465
  Location                  uncinate                25                     1                                           1                     
                            non-uncinate            50                     0.405 (0.227-0.721)   0.002                 0.409 (0.231-0.724)   0.002
  CA 19-9                                                                  1.001 (1.000-1.002)   0.093                 1.001 (1.000-1.002)   0.046
  Venous resection          no                      52                     1                                           1                     
                            yes                     13                     0.995 (0.496-1.997)   0.989                 1.353 (0.701-2.611)   0.367
  T stage                   T1/T2                   55                     1                                           1                     
                            T3                      10                     0.976 (0.456-2.092)   0.951                 0.910 (0.425-1.951)   0.809
  Tumor size (mm)                                                          1.007 (0.992-1.023)   0.372                 1.011 (0.996-1.027)   0.144
  Tumor differentiation     Well-Moderate           16                     1                                           1                     
  Moderate-Poor             49                      2.278 (1.102-4.4707)   0.026                 1.721 (0.860-3.447)   0.125                 
  Margins                   R0                      51                     1                                           1                     
                            R1                      14                     3.401 (1.716-6.741)   0.001                 2.879 (1.478-5.612)   0.002
  LN metastasis             negative                35                     1                                           1                     
                            positive                30                     2.378 (1.330-4.253)   0.003                 2.633 (1.451-4.779)   0.001
                                                                                                                                             
  N0. of positive LN                                                       1.365 (1.176-1.584)   \<0.001               1.253 (1.093-1.437)   0.001
  AJCC stage                IB                      7                      1                                           1                     
                            IIA                     28                     0.860 (0.316-2.341)   0.768                 0.891 (0.325-2.442)   0.822
                            IIB                     30                     2.115 (0.809-5.531)   0.127                 2.411 (0.919-6.323)   0.074
                                                                                                                                             
  Perineural invasion       no                      14                     1                                           1                     
  yes                       51                      1.360 (0.660-2.805)    0.405                 1.200 (0.598-2.409)   0.607                 
  Vascular cancer embolus   no                      50                     1                                           1                     
  yes                       15                      2.072 (1.103-3.894)    0.024                 1.663 (0.880-3.144)   0.118                 
  Chemotherapy              no                      43                     1                                           1                     
                            yes                     22                     0.767 (0.413-1.424)   0.401                 0.826 (0.452-1.512)   0.536

HR, Hazard ratio; 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer.

###### 

Multivariate analysis of disease-free and overall survival of patients after resection.

  -------------------------------------------------------------------------------------------------------------------------------------
                            disease-free survival   overall survival                                                          
  ------------------------- ----------------------- ------------------ --------------------- --------- ---------------------- ---------
  Location                                                                                   \<0.001                          \<0.001

                            uncinate                25                 1                               1                      

                            non-uncinate            50                 0.299 (0.155-0.577)             0.309 (0.160-0.596)    

  CA 19-9                                                              1.000 (0.999-1.001)   0.488     1.000 (1.000-1.001)    0.331

  Tumor differentiation                                                                      0.076                            0.394

                            well                    16                 1                               1                      

                            moderate/\              49                 1.959 (0.932-4.116)             1.3378 (0.660-2.880)   
                            poor                                                                                              

  Margins                                                                                    0.028                            0.263

                            R0                      51                 1                               1                      

                            R1                      14                 2.278 (1.092-4.750)             1.523 (0.729-3.181)    

  LN metastasis                                                                              0.002                            0.002

                            negative                35                 1                               1                      

                            positive                30                 2.847 (1.456-5.566)             3.084 (1.524-6.242)    

  Vascular cancer embolus                                                                    0.067                            0.352

                            no                      50                 1                               1                      

                            yes                     15                 1.852 (0.958-3.580)             1.366 (0.708-2.638)    
  -------------------------------------------------------------------------------------------------------------------------------------

HR, Hazard ratio; 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer.
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